Who Optimizes SG&A Costs Better? AstraZeneca PLC or Incyte Corporation

Optimizing SG&A Costs: AstraZeneca vs. Incyte

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. AstraZeneca PLC and Incyte Corporation, two prominent players, have shown contrasting approaches over the past decade.

From 2014 to 2023, AstraZeneca's SG&A expenses have seen a significant increase, peaking at approximately $18 billion in 2022. This represents a growth of over 40% from their 2016 low. In contrast, Incyte Corporation has maintained a more conservative approach, with expenses rising from $166 million in 2014 to just over $1 billion in 2023, marking a sixfold increase.

While AstraZeneca's strategy reflects aggressive expansion and investment, Incyte's careful cost management highlights a focus on efficiency. This comparison offers valuable insights into how different strategies can impact financial health in the pharmaceutical sector.